Related Experiment Videos
[Correction of hyperdyslipidemia using polyene-structure substances. Controlled clinical trial]
Archivio Per Le Scienze Mediche
|April 1, 1979
Summary
Mepartricin demonstrated a positive fat-lowering effect in patients with lipid disorders, showing a better therapeutic index and good tolerance compared to clofibrate.
Area of Science:
- Pharmacology
- Clinical Therapeutics
- Lipid Metabolism
Background:
- Dyslipidemia is a significant risk factor for cardiovascular diseases.
- Existing lipid-lowering drugs have varying efficacy and side effect profiles.
Purpose of the Study:
- To evaluate the efficacy and safety of mepartricin in patients with lipid disorders.
- To compare mepartricin with clofibrate, a known lipid-lowering agent.
Main Methods:
- A randomized, cross-over trial involving 20 patients with various lipid disorders.
- Patients received mepartricin (SPA-S-160 enteric-coated tablets) and clofibrate, 3 tablets daily for 30 days each.
- A 30-day drug-free interval separated the treatment periods.
Main Results:
- Both mepartricin and clofibrate showed positive effects on lipid levels.
- Mepartricin exhibited a superior therapeutic index compared to clofibrate.
- Both drugs were well-tolerated locally and systemically.
- Higher transaminase levels were observed after clofibrate treatment.
Conclusions:
- Mepartricin is an effective and well-tolerated option for managing lipid disorders.
- Mepartricin presents a favorable alternative to clofibrate, with improved safety profile regarding liver enzymes.